MPC-7869. Prostate cancer therapy treatment of Alzheimer's dementia

Drugs of the Future

Volumn 31, Issue 1, 2006, Pages 22-27

  McIntyre, J A ^a   Castaner J ^a   Fernandez Forner D ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; E 7869; FLURBIPROFEN; FLURIZAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MPC 7869; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; ZYMOSAN;

ADENOMATOUS POLYP; ALZHEIMER DISEASE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL STRAIN CACO 2; CELL STRAIN HEK293; CELL STRAIN U937; CHEMOPROPHYLAXIS; CHO CELL; DEMENTIA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENANTIOMER; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLIOMA CELL; HUMAN; MOUSE STRAIN; NEUROLOGIC DISEASE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; RAT STRAIN; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TRANSGENIC MOUSE; ULCEROGENESIS; VOLUNTEER;

EID: 33645552739     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.01.961798     Document Type: Article

References (48)

1. Adams, S.S., Bernard, J., Nicholson, J.S., Ribera Blancafort, A. (The Boots Company plc). 2-(Mono- and difluoro-4-biphenyl)propionic acids. US 3755427.
2. Walker, J.A. (Pfizer Inc.). Processes for the preparation of hydratropic acids and esters. US 4266069, JP 1981097247.
3. Nicholson, J.S., Turner, J.L. (The Boots Company plc). Preparation of therapeutic compounds. DE 2613817, FR 2306192, GB 1514812, JP 1976127042, JP 1981095147, US 4188491, US 4304931.
4. Hardy, R., Coe, P.F., Hirst, A., O'Donnell, H.O. (The Boots Company plc). Process for preparing substantially pure enantiomers of phenylpropionic acids. WO 1994012460.
5. Takahashi, K., Takeda, T. (Sumitomo Pharmaceuticals Co., Ltd.). Method of preparing optically active carboxylic acid. JP 2000143580.
6. Morrone, R., Nicolosi, G., Patti, A., Piattelli, M. Resolution of racemic flurbiprofen by lipase-mediated esterification in organic solvent. Tetrahedron Asymmetry 1995, 6: 1773-8.
7. Terao, Y., Ijima, Y., Kakidani, H., Ohta, H. Enzymatic synthesis of (R)-flurbiprofen. Bull Chem Soc Jpn 2003, 76: 2395-7.
8. Hanzawa, S., Kakitani, H., Ohta, H. (Tosoh Corp.). Method of preparing optically active α-arylpropionic acid. JP 2003169691.
9. Young, C.Y.F. The role of nonsteroidal antiinflammatory drugs in cancer chemoprevention. Drugs Fut 2004, 29: 467-78.
10. Nelson, J.E., Harris, R.E. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study. Oncol Rep 2000, 7: 169-70.
11. Roberts, R.O., Jacobson, D.J., Girman, C.J., Rhodes, T., Lieber, M.M., Jacobsen, S.J. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002, 77: 219-25.
12. In't Veld, B.A., Ruitenberg, A., Hofman, A., Launer, L.J., van Duijn, C.M., Stijnen, T., Breteler, M.M.B., Stricker, B.H.C. Nonsteroidal antiinflammatory drugs and risk of Alzheimer's disease. New Engl J Med 2001, 345: 1515-21.
13. Etminan, M., Gill, S., Sar, A. Effect of non-steroidal antiinflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. BMJ - Br Med J 2003, 327: 128-32.
14. Szekely, C.A., Thorne, J.E., Zandi, P.P., Ek, M., Messias, E., Breitner, J.C., Goodman, S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology 2004, 23: 159-69.
15. Wechter, W.J., Leipold, D.D., Quiggle, D.D., McCracken, J.D., Murray, E.D. Jr., Loughman, B.E. R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer. Inflammopharmacology 2000, 8: 189-206.
16. Riendeau, D., Charleson, S., Cromlish, W. et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol 1997, 75(9): 1088-95.
17. Gasparini, L., Ongini, E., Wilcock, D., Morgan, D. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Rev 2005, 48: 400-8.
18. Morihara, T., Chu, T., Ubeda, O., Beech, W., Cole, G.M. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J Neurochem 2002, 83: 1009-12.
19. Morihara, T., Chu, T., Ubeda, O., Beech, W., Teter, B., Frautschy, S., Cole, G.M. Novel NSAIDs with limited toxicity and their targets in suppressing Alzheimer pathogenesis. 8th Int Conf Alzheimer's Dis Relat Disord (July 20-25, Stockholm) 2002, Abst 1519.
20. Eriksen, J.L., Sagi, S.A., Smith, T.E. et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J Clin Invest 2003, 112: 440-9.
21. Eriksen, J.L., Nicolle, M.M., Prescott, S. et al. Chronic treatment of transgenic APP mice with R-flurbiprofen. 33rd Annu Meet Soc Neurosci (Nov 8-12, New Orleans) 2003, Abst 295.22.
22. Nicolle, M.M., Prescott, S., Murphy, M.P., Kukar, T., Eriksen, J.L., Koo, E.H., Golde, T.E. Long-term, but not short-term, R-flurbiprofen treatment ameliorates cognitive deficits in transgenic APP mice. 34th Annu Meet Soc Neurosci (Oct 23-27, San Diego) 2004, Abst 674.6.
23. McCracken, J.D., Wechter, W.J., Liu, Y., Chase, R.L., Kantoci, D., Murray, E.D. Jr., Quiggle, D.D. Mineyama, Y. Antiproliferative effects of the enantiomers of flurbiprofen. J Clin Pharmacol 1996, 36: 540-5.
24. McCracken, J.D., Wechter, W.J., Quiggle, D., Liu, Y.J., Chase, R., Mineyama, Y. R-Isomer of flurbiprofen decreases colonic cell proliferation without causing significant small bowel ulceration. J Clin Pharmacol 1996, 36(6): Abst 4.
25. Min/+ mouse model: Implications for prophylaxis and treatment of colon cancer. Cancer Res 1997, 57: 4316-24.
26. Min/+ (Min) mouse with R-flurbiprofen. Life Sci 2000, 66: 745-53.
27. Min/+ mouse with R-flurbiprofen (R-FB) and sulindic sulfone (SS). Proc Am Assoc Cancer Res (AACR) 1998, 39: Abst 4381.
28. Wechter, W.J., Leipold, D.D., Murray, E.D. Jr., Quiggle, D., McCracken, J.D., Barrios, R.S., Greenberg, N.M. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000, 60: 2203-8.
29. Chen, C.-S., Reiter, R., Zemskova, M., Lilly, M. Gene expression profiling in prostate cancer treated with R-flurbiprofen: Identification of prostate stem-cell antigen as a flurbiprofen-regulated gene. 3rd Annu Int Conf Front Cancer Prev Res (Oct 16-20, Seattle) 2004, Abst A72.
30. McCracken, J.D., Godil, A., Murray, E.D., Kantoci, D., Gridley, D., Andres, M., Langridge, W., Pant, K.D., Wechter, W.J. R-Flurbiprofen suppresses LS174T xenograft growth in the nude rat. Proc Am Assoc Cancer Res (AACR) 1998, 39: Abst 2146.
31. Chaudhary, K.K., McCracken, J.D., Pappas, J.M., Berk, L.S., Santamaria, D.A. Cyclooxygenase-2 gene expression is reduced by R-flurbiprofen in a human colon cancer xenograft. J Invest Med 1999, 47(2): 47A.
32. Tegeder, I., Niederberger, E., Israr, E., Gühring, H., Brune, K., Euchenhofer, C., Grösch, S., Geisslinger, G. Inhibition of NF-κB and AP-1 activation by R-and S-flurbiprofen. FASEB J 2001, 15: 2-4.
33. Grösch, S., Tedegar, I., Schilling, K., Maier, T., Niederberger, E., Geisslinger, G. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J 2003, 17: 1316-8.
34. Grösch, S., Schilling, K., Janssen, A., Maier, T.J., Niederberger, E., Geisslinger, G. Induction of apoptosis by R-flurbiprofen in human colon carcinoma cells: Involvement of p53. Biochem Pharmacol 2005, 69: 831-9.
35. Murray, E.D. Jr., Quiggle, D., Gibson, K., Leipold, D., Loughman, B., Wechter, W. Phase I single-dose pharmacokinetics and lack of enantiomeric bioinversion of E-7869 (R-flurbiprofen). Clin Pharmacol Ther 2000, 67(2): Abst PI-56.
36. Wechter, W.J., Bigornia, A.E., Murray, E.D. Jr., Levine, B.H., Young, J.W. Rac-flurbiprofen is more ulcerogenic than its (S)-enantiomer. Chirality 1993, 5: 492-4.
37. Wilcock, G., Black, S., Haworth, J., Laughlin, M., Hendrix, S., Binger, M.-H., Zavitz, K., Swabb, E., Hobden, A. Flurizan, (MPC-7869, (R)-flurbiprofen) a selective Aβ-42 lowering agent in patients with mild to moderate Alzheimer's disease: A randomised, placebo-controlled, double blind trial. Int Psychogeriatr 2005, 17(Suppl. 2): Abst FC7.4.
38. Wilcock, G., Black, S., Haworth, J., Laughlin, M., Hendrix, S., Binger, M.-H., Zavitz, K., Swabb, E., Hobben, A. A placebo-controlled, double-blind trial of the selective Aβ-42 lowering agent, Flurizan (MPC-7869, (R)-flurbiprofen) in patients with mild to moderate Alzheimer's disease. Alzheimer's Assoc Int Conf Prev Dement (June 18-21, Washington DC) 2005, Abst 02-01-05.
39. Black, S., Wilcock, G., Haworth, J., Hendrix, S., Zavitz, K., Binger, M., Roch, J., Laughlin, M., Swabb, E., Hobden, A. A placebo-controlled, double-blind trial of the selective Aβ42-lowering agent Flurizan in patients with mild to moderate Alzheimer's disease: Efficacy, safety, and follow-on study results. 35th Annu Meet Soc Neurosci (Nov 12-16, Washington DC) 2005, Abst 586.6.
40. Phase III Flurizan trial enrolling on schedule. DailyDrugNews.com (Daily Essentials) August 8, 2005.
41. Preliminary data on the efficacy of Flurizan in Alzheimer's disease. DailyDrugNews.com (Daily Essentials) May 5, 2005.
42. Flurizan taken beyond 1 year improved cognition in Alzheimer's disease patients. DailyDrugNews.com (Daily Essentials) November 25, 2005.
43. Swabb, E.A., Quiggle, D.D., Gutierrez, I., Murray, E.D. Jr., Reid, J.E., Wechter, W.J., Loughman, B.E. Multi-dose phase IIa trial of MPC-7869 in prostate cancer patients with increasing prostate specific antigen (PSA). Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst 3714.
44. Lilly, M., Ruckle, H., Quiggle, D., Gutierrez, I., Murray, E.D., Gibson, K., Leipold, D., Wechter, W.J., Loughman, B. Multi-dose phase I-II trial of E-7869 in prostate cancer patients: Safety and time to PSA progression (TPSAP). Proc Am Assoc Cancer Res (AACR) 2001, 42: Abst 763.
45. Quiggle, D.D., Lilly, M., Murray, E.D., Gibson, K.M., Leipold, D.D., Gutierrez, I., Loughman, B.E., Wechter, W.J. PK guided multi-dose, tolerance and safety of E-7869 in prostate cancer patients. Proc Am Assoc Cancer Res (AACR) 2000, 41: Abst 3874.
46. Enrollment begins in phase III Alzheimer's study of Flurizan. DailyDrugNews.com (Daily Essentials) January 14, 2005.
47. Efficacy study of MPC-7869 to treat patients with Alzheimer's (NCT00105547). ClinicalTrials.gov Web Site 2005, December 8.
48. R-Flurbiprofen in treating patients with localized prostate cancer at risk of recurrence (NCT00045123). ClinicalTrials.gov Web Site 2005, December 8.